IPGA-05

N/A

Report date: 2025/12/19 16:31:27

Base Information

Drug NameIPGA-05
Drug Alias NameIPGA-05IPG0521IPG-0521
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumoursImmunoglobulin G4-Related DiseaseAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Immunophage Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Immunophage Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursImmunoglobulin G4-Related DiseaseAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A